Abbott inks pact with Astellas Pharma in Phase 3 clinical trial for ASP0113

By Admin
Abbott said it has signed a pact to collaborate with Astellas Pharma Global Development in a Phase 3 clinical trial for ASP0113. ASP00113 is an investi...

Abbott said it has signed a pact to collaborate with Astellas Pharma Global Development in a Phase 3 clinical trial for ASP0113.

ASP00113 is an investigational vaccine licensed from Vical Incorporated for preventing cytomegalovirus reactivation in transplant patients.

As per the agreement signed, Abbott’s RealTime CMV assay will be used to monitor patients for CMV viral load to assess the vaccine’s efficacy.

John Coulter, Head of Abbott’s molecular diagnostics business said, “Our agreement with Astellas gives us an opportunity to collaborate with another leader in the healthcare industry to better monitor patients to ensure proper treatment.”

Mr.  Coulter also said, “Abbott’s investigational CMV test will be used as an important aid in assessing the efficacy of this promising vaccine which could significantly improve the overall outcome of transplant procedures.”

This deal represents the fourth collaboration signed by Abbot in the last 12 months with a leading pharmaceutical company.

Its recent partnerships with GlaxoSmithKline, Pfizer, and Merck focuses on developing companion diagnostic tests for novel oncology therapeutics and focusing on developing of companion diagnostic tests.

Abbott is a global, broad-based healthcare company involved in discovery, development, manufacturing and marketing of pharmaceutical and medical products. Astellas Pharma is a Japanese pharmaceutical company formed through the merger of Yamanouchi Pharmaceutical Co. Ltd and Fujisawa Pharmaceutical Co. Ltd. It has its headquarters in Tokyo.

Share
Share

Featured Articles

Siemens: smart finance to help medical technology growth

Penny Pinnock, Business Development Manager at Siemens Financial Services UK, discusses how adopting digital technology can support the healthcare sector

Healthcare Digital news roundup: prostate cancer & AI

This week in Healthcare Digital, we heard from experts in the sector: Trevor Dearing from Illumio, Avenda Health’s Brit Berry-Pusey & Vish Charan of Abbott

Lexica shares post-COVID-19 digital healthcare trends

Joanna Smith, Digital Advisory Lead at consulting company Lexica, explores the impact of COVID-19 on digital healthcare & what role health data can play

Medical devices expanding senior healthcare innovation

Medical Devices & Pharma

Abbott’s CRM medical devices can help cardiac arrhythmia

Medical Devices & Pharma

AutoRABIT CEO Meredith Bell on DevOps strategy in healthcare

Hospitals